行情

ADRO

ADRO

Aduro Biotech
NASDAQ

实时行情|Nasdaq Last Sale

1.180
-0.040
-3.28%
盘后: 1.180 0 0.00% 16:24 09/20 EDT
开盘
1.210
昨收
1.220
最高
1.230
最低
1.180
成交量
57.43万
成交额
--
52周最高
7.64
52周最低
1.150
市值
9,456.55万
市盈率(TTM)
-1.0259
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADRO 新闻

  • Do Insiders Own Lots Of Shares In Aduro BioTech, Inc. (NASDAQ:ADRO)?
  • Simply Wall St..2天前
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.09/04 15:39
  • Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
  • GlobeNewswire.09/04 13:30
  • The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
  • Benzinga.09/04 11:08

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ADRO 简况

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
展开

Webull提供Aduro BioTech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。